BioInvent To Cut Jobs By A Quarter Following Head-To-Head Clinical Trial Disappointment
This article was originally published in The Pink Sheet Daily
Sweden's antibody platform company BioInvent moves quickly to reorganize following disappointing Phase IIb clinical results with a potential antithrombotic antibody.
You may also be interested in...
Sweden's BioInvent forges links with researchers at Queen Mary, University of London, and Cancer Research Technology, the commercial arm of charity Cancer Research UK, to identify new therapeutic antibodies for oncology.
Next-generation antibody company Ablynx boasts a series of technology partnership deals but its primary goal is to develop drugs. Can partners’ money fund a pipeline with sufficient focus to be manageable, but enough breadth to survive?
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.